董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Aimee Weisner | 女 | Director | 51 | 未披露 | 未持股 | 2019-10-31 |
| Ali Behbahani | 男 | Director | 43 | 未披露 | 未持股 | 2019-10-31 |
| Jeffrey Nau | 男 | President, Chief Executive Officer and Director | 44 | 39.00万美元 | 未持股 | 2019-10-31 |
| Michael Ackermann | 男 | Chairperson of the Board | 37 | 10.00万美元 | 未持股 | 2019-10-31 |
| Mark Murray | 男 | Director | 60 | 33.62万美元 | 未持股 | 2019-10-31 |
| Clare Ozawa | 女 | Director | 45 | 未披露 | 未持股 | 2019-10-31 |
| Benjamin Tsai | 男 | Director | 40 | 未披露 | 未持股 | 2019-10-31 |
| William J. Link | 男 | Director | 73 | 未披露 | 未持股 | 2019-10-31 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Jeffrey Nau | 男 | President, Chief Executive Officer and Director | 44 | 39.00万美元 | 未持股 | 2019-10-31 |
| Daniel Lochner | 男 | Chief Financial Officer | 37 | 未披露 | 未持股 | 2019-10-31 |
| John Snisarenko | 男 | Chief Commercial Officer | 56 | 未披露 | 未持股 | 2019-10-31 |
董事简历
中英对照 | 中文 | 英文- Aimee Weisner
-
Aimee Weisner，2014年1月以来，她曾一直担任我们董事会的成员。她目前担任Edwards Lifesciences Corporation的公司副总裁，以及首席法律顾问（2011年1月以来）。从2009年到2010年，她曾从事私人诊所，担任加州南部上市药品和医疗设备公司的法律顾问。此前，她曾担任Advanced Medical Optics公司的多种职务（从2002年到2009年），包括公司副总裁、总法律顾问和秘书、执行行政副总裁、法律顾问和秘书、执行行政副总裁、秘书。从1998年到2002年，她曾担任Allergan公司的企业法律顾问兼助理秘书，以及副总裁、助理总法律顾问和助理秘书。她持有加州州立大学富尔顿分校（CaliforniaStateUniversity,Fullerton）的通信学士学位、洛杉矶罗耀拉法学院（Loyola Law School）的法学学位。她的职业生涯始于担任O’Melveny & Myers公司的律师事务所合伙人。
Aimee Weisner will be joining our board of directors effective immediately after the effectiveness of the registration statement of which this prospectus forms a part. From January 2011 to July 2019 Ms. Weisner served as the General Counsel and as a corporate vice president at Edwards Lifesciences Corporation. Prior to Edwards Lifesciences, Ms. Weisner served as a legal advisor to public pharmaceutical and medical device companies located in Southern California from 2009 to 2010. From 2002 to 2009 Ms. Weisner served in several positions at Advanced Medical Optics, Inc. acquired by Abbott Laboratories, including corporate vice president, general counsel and secretary; executive vice president, administration, general counsel and secretary; and executive vice president, administration and secretary. From 1998 to 2002 Ms. Weisner served as corporate counsel and assistant secretary; and then vice president, assistant general counsel and assistant secretary at Allergan, Inc. Since July 2014 Ms. Weisner has served as a member of the board of directors of Glaukos Corporation (NYSE:GKOS). Ms. Weisner received a B.A. from California State University, Fullerton and a J.D. from Loyola Law School, Los Angeles. - Aimee Weisner，2014年1月以来，她曾一直担任我们董事会的成员。她目前担任Edwards Lifesciences Corporation的公司副总裁，以及首席法律顾问（2011年1月以来）。从2009年到2010年，她曾从事私人诊所，担任加州南部上市药品和医疗设备公司的法律顾问。此前，她曾担任Advanced Medical Optics公司的多种职务（从2002年到2009年），包括公司副总裁、总法律顾问和秘书、执行行政副总裁、法律顾问和秘书、执行行政副总裁、秘书。从1998年到2002年，她曾担任Allergan公司的企业法律顾问兼助理秘书，以及副总裁、助理总法律顾问和助理秘书。她持有加州州立大学富尔顿分校（CaliforniaStateUniversity,Fullerton）的通信学士学位、洛杉矶罗耀拉法学院（Loyola Law School）的法学学位。她的职业生涯始于担任O’Melveny & Myers公司的律师事务所合伙人。
- Aimee Weisner will be joining our board of directors effective immediately after the effectiveness of the registration statement of which this prospectus forms a part. From January 2011 to July 2019 Ms. Weisner served as the General Counsel and as a corporate vice president at Edwards Lifesciences Corporation. Prior to Edwards Lifesciences, Ms. Weisner served as a legal advisor to public pharmaceutical and medical device companies located in Southern California from 2009 to 2010. From 2002 to 2009 Ms. Weisner served in several positions at Advanced Medical Optics, Inc. acquired by Abbott Laboratories, including corporate vice president, general counsel and secretary; executive vice president, administration, general counsel and secretary; and executive vice president, administration and secretary. From 1998 to 2002 Ms. Weisner served as corporate counsel and assistant secretary; and then vice president, assistant general counsel and assistant secretary at Allergan, Inc. Since July 2014 Ms. Weisner has served as a member of the board of directors of Glaukos Corporation (NYSE:GKOS). Ms. Weisner received a B.A. from California State University, Fullerton and a J.D. from Loyola Law School, Los Angeles.
- Ali Behbahani
-
Ali Behbahani，自2020年4月起担任Monte Rosa治疗公司董事会成员。Behbahani博士于2007年加入风险投资公司New Enterprise Associates，Inc.，是医疗保健部门的合伙人和联席主管。在加入New Enterprise Associates，Inc.之前，Behbahani博士曾于1998年至2000年在制药公司The Medicines Company担任业务发展顾问，在跨国投资银行和金融服务公司摩根士丹利担任风险投资助理，在全球金融服务公司雷曼兄弟担任医疗保健投资银行分析师。Behbahani博士担任生物技术公司Nkarta, Inc.的董事会成员，自2015年8月起，生物制药公司Black Diamond Therapeutics, Inc.，生物制药公司，自2018年12月起，生物制药公司Adaptimmune治疗 PLC，自2014年9月起，生物技术公司CRISPR Therapeutics AG，自2015年3月起，生物技术公司Korro Bio，Inc.，自2019年8月起，生物技术公司Arcellx, Inc.，自2015年2月起。Behbahani博士曾于2013年7月至2024年9月担任医疗器械公司CVRx, Inc.的董事会成员，全球医疗器械公司Nevro Corp.，2014年8月至2019年3月，生物制药公司Oyster Point Pharma, Inc.，2017年7月至2023年1月，生物制药公司Genocea Biosciences, Inc.，2018年2月至2022年5月，生物技术公司Minerva Surgical，2011年5月至2024年1月，以及生物技术公司TERM4，Inc.至2017年。Behbahani博士获得了宾夕法尼亚大学医学院的医学博士学位、宾夕法尼亚大学沃顿商学院的工商管理硕士学位以及杜克大学的生物医学工程、电气工程和化学学士学位。
Ali Behbahani,has been a member of Monte Rosa Therapeutics, Inc. board of directors since April 2020. Dr. Behbahani joined New Enterprise Associates, Inc., a venture capital firm, in 2007 and is a Partner and Co-Head of Healthcare. Prior to joining New Enterprise Associates, Inc., Dr. Behbahani served as a consultant in business development at The Medicines Company, a pharmaceutical company, a Venture Associate at Morgan Stanley, a multinational investment bank and financial services company, and a Healthcare Investment Banking Analyst at Lehman Brothers, a global financial services firm, from 1998 to 2000. Dr. Behbahani serves as a member of the board of directors of Nkarta, Inc., a biotechnology company, since August 2015, Black Diamond Therapeutics, Inc., a biopharmaceutical company, since December 2018, Adaptimmune Therapeutics plc, a biopharmaceutical company, since September 2014, CRISPR Therapeutics AG, a biotechnology company, since March 2015, Korro Bio, Inc., a biotechnology company, since August 2019, and Arcellx, Inc., a biotechnology company, since February 2015. Dr. Behbahani formerly served as a member of the board of directors of CVRx, Inc., a medical device company, from July 2013 to September 2024, Nevro Corp., a global medical device company, from August 2014 to March 2019, Oyster Point Pharma, Inc., a biopharmaceutical company, from July 2017 to January 2023, Genocea Biosciences, Inc., a biopharmaceutical company, from February 2018 to May 2022, Minerva Surgical Inc., a biotechnology company, from May 2011 to January 2024, and Marker Therapeutics, Inc. until 2017. Dr. Behbahani received an M.D. from the University of Pennsylvania School of Medicine, an M.B.A. from the Wharton School of the University of Pennsylvania and a B.S. in biomedical engineering, electrical engineering and chemistry from Duke University. - Ali Behbahani，自2020年4月起担任Monte Rosa治疗公司董事会成员。Behbahani博士于2007年加入风险投资公司New Enterprise Associates，Inc.，是医疗保健部门的合伙人和联席主管。在加入New Enterprise Associates，Inc.之前，Behbahani博士曾于1998年至2000年在制药公司The Medicines Company担任业务发展顾问，在跨国投资银行和金融服务公司摩根士丹利担任风险投资助理，在全球金融服务公司雷曼兄弟担任医疗保健投资银行分析师。Behbahani博士担任生物技术公司Nkarta, Inc.的董事会成员，自2015年8月起，生物制药公司Black Diamond Therapeutics, Inc.，生物制药公司，自2018年12月起，生物制药公司Adaptimmune治疗 PLC，自2014年9月起，生物技术公司CRISPR Therapeutics AG，自2015年3月起，生物技术公司Korro Bio，Inc.，自2019年8月起，生物技术公司Arcellx, Inc.，自2015年2月起。Behbahani博士曾于2013年7月至2024年9月担任医疗器械公司CVRx, Inc.的董事会成员，全球医疗器械公司Nevro Corp.，2014年8月至2019年3月，生物制药公司Oyster Point Pharma, Inc.，2017年7月至2023年1月，生物制药公司Genocea Biosciences, Inc.，2018年2月至2022年5月，生物技术公司Minerva Surgical，2011年5月至2024年1月，以及生物技术公司TERM4，Inc.至2017年。Behbahani博士获得了宾夕法尼亚大学医学院的医学博士学位、宾夕法尼亚大学沃顿商学院的工商管理硕士学位以及杜克大学的生物医学工程、电气工程和化学学士学位。
- Ali Behbahani,has been a member of Monte Rosa Therapeutics, Inc. board of directors since April 2020. Dr. Behbahani joined New Enterprise Associates, Inc., a venture capital firm, in 2007 and is a Partner and Co-Head of Healthcare. Prior to joining New Enterprise Associates, Inc., Dr. Behbahani served as a consultant in business development at The Medicines Company, a pharmaceutical company, a Venture Associate at Morgan Stanley, a multinational investment bank and financial services company, and a Healthcare Investment Banking Analyst at Lehman Brothers, a global financial services firm, from 1998 to 2000. Dr. Behbahani serves as a member of the board of directors of Nkarta, Inc., a biotechnology company, since August 2015, Black Diamond Therapeutics, Inc., a biopharmaceutical company, since December 2018, Adaptimmune Therapeutics plc, a biopharmaceutical company, since September 2014, CRISPR Therapeutics AG, a biotechnology company, since March 2015, Korro Bio, Inc., a biotechnology company, since August 2019, and Arcellx, Inc., a biotechnology company, since February 2015. Dr. Behbahani formerly served as a member of the board of directors of CVRx, Inc., a medical device company, from July 2013 to September 2024, Nevro Corp., a global medical device company, from August 2014 to March 2019, Oyster Point Pharma, Inc., a biopharmaceutical company, from July 2017 to January 2023, Genocea Biosciences, Inc., a biopharmaceutical company, from February 2018 to May 2022, Minerva Surgical Inc., a biotechnology company, from May 2011 to January 2024, and Marker Therapeutics, Inc. until 2017. Dr. Behbahani received an M.D. from the University of Pennsylvania School of Medicine, an M.B.A. from the Wharton School of the University of Pennsylvania and a B.S. in biomedical engineering, electrical engineering and chemistry from Duke University.
- Jeffrey Nau
-
Jeffrey Nau自2017年10月起担任我们的总裁兼首席执行官，并担任我们的董事会成员。从2017年3月至2017年10月，瑙博士作为顾问为我们提供服务。此前，Nau博士于2013年7月至2017年3月担任临床阶段生物制药公司Ophthotech Corporation Ophthotech临床和医疗事务Vice President。任职Ophthotech公司之前，他曾担任Genentech公司（生物技术公司）的医学科学董事（从2011年10月到2013年7月）。2006年9月至2011年10月，Nau博士担任Neovista的医疗和临床事务Vice President。Nau博士在石溪大学（Stony Brook University）获得生物学学士学位，在德雷克塞尔大学医学院（Drexel University College of Medicine）获得医学硕士学位，在沃尔登大学（Walden University）获得公共卫生与流行病学博士学位。
Jeffrey Nau has served as our President and Chief Executive Officer and as a member of our board of directors since October 2017. From March 2017 to October 2017 Dr. Nau provided services to us as a consultant. Previously, Dr. Nau was Vice President of Clinical and Medical Affairs at Ophthotech Corporation Ophthotech, a clinical-stage biopharmaceuticals company, from July 2013 to March 2017. Prior to Ophthotech, he was a Medical Science Director at Genentech, a biotechnology company, from October 2011 to July 2013. From September 2006 to October 2011 Dr. Nau was Vice President of Medical and Clinical Affairs at NeoVista. Dr. Nau received a B.S. in Biology from Stony Brook University, an M.S. in medical science from Drexel University College of Medicine, and a Ph.D. in public health and epidemiology from Walden University. - Jeffrey Nau自2017年10月起担任我们的总裁兼首席执行官，并担任我们的董事会成员。从2017年3月至2017年10月，瑙博士作为顾问为我们提供服务。此前，Nau博士于2013年7月至2017年3月担任临床阶段生物制药公司Ophthotech Corporation Ophthotech临床和医疗事务Vice President。任职Ophthotech公司之前，他曾担任Genentech公司（生物技术公司）的医学科学董事（从2011年10月到2013年7月）。2006年9月至2011年10月，Nau博士担任Neovista的医疗和临床事务Vice President。Nau博士在石溪大学（Stony Brook University）获得生物学学士学位，在德雷克塞尔大学医学院（Drexel University College of Medicine）获得医学硕士学位，在沃尔登大学（Walden University）获得公共卫生与流行病学博士学位。
- Jeffrey Nau has served as our President and Chief Executive Officer and as a member of our board of directors since October 2017. From March 2017 to October 2017 Dr. Nau provided services to us as a consultant. Previously, Dr. Nau was Vice President of Clinical and Medical Affairs at Ophthotech Corporation Ophthotech, a clinical-stage biopharmaceuticals company, from July 2013 to March 2017. Prior to Ophthotech, he was a Medical Science Director at Genentech, a biotechnology company, from October 2011 to July 2013. From September 2006 to October 2011 Dr. Nau was Vice President of Medical and Clinical Affairs at NeoVista. Dr. Nau received a B.S. in Biology from Stony Brook University, an M.S. in medical science from Drexel University College of Medicine, and a Ph.D. in public health and epidemiology from Walden University.
- Michael Ackermann
-
Michael Ackermann自2017年7月起担任董事会成员和董事会主席。Ackermann博士自2017年9月起担任Presidio Medical，Inc.的首席执行官。从2017年10月至2020年10月，阿克曼先生担任Oyster Point Pharma的董事会主席。在此之前，他于2015年8月至2017年6月担任Allergan的神经刺激部Vice President，2012年6月至2015年8月担任Oculeve的首席执行官，后者被Allergan收购。Ackermann博士在范德堡大学（Vanderbilt University）获得生物医学工程学士学位，并在凯斯西储大学（Case Western Reserve University）获得生物医学工程硕士和博士学位。
Michael Ackermann has served as a member of our board of directors and as chairperson of our board of directors since July 2017. Dr. Ackermann has been the Chief Executive Officer of Presidio Medical, Inc. since September 2017. From October 2017 until October 2020 Mr. Ackermann served as the chairman of the board of Oyster Point Pharma. Prior to that, he was Vice President, Neurostimulation for Allergan from August 2015 to June 2017 after serving as Chief Executive Officer of Oculeve, which was acquired by Allergan, from June 2012 to August 2015. Dr. Ackermann received a B.E. in biomedical engineering from Vanderbilt University and a M.S. and Ph.D. in biomedical engineering from Case Western Reserve University. - Michael Ackermann自2017年7月起担任董事会成员和董事会主席。Ackermann博士自2017年9月起担任Presidio Medical，Inc.的首席执行官。从2017年10月至2020年10月，阿克曼先生担任Oyster Point Pharma的董事会主席。在此之前，他于2015年8月至2017年6月担任Allergan的神经刺激部Vice President，2012年6月至2015年8月担任Oculeve的首席执行官，后者被Allergan收购。Ackermann博士在范德堡大学（Vanderbilt University）获得生物医学工程学士学位，并在凯斯西储大学（Case Western Reserve University）获得生物医学工程硕士和博士学位。
- Michael Ackermann has served as a member of our board of directors and as chairperson of our board of directors since July 2017. Dr. Ackermann has been the Chief Executive Officer of Presidio Medical, Inc. since September 2017. From October 2017 until October 2020 Mr. Ackermann served as the chairman of the board of Oyster Point Pharma. Prior to that, he was Vice President, Neurostimulation for Allergan from August 2015 to June 2017 after serving as Chief Executive Officer of Oculeve, which was acquired by Allergan, from June 2012 to August 2015. Dr. Ackermann received a B.E. in biomedical engineering from Vanderbilt University and a M.S. and Ph.D. in biomedical engineering from Case Western Reserve University.
- Mark Murray
-
Mark Murray自2017年10月起担任董事会成员，此前曾于2017年11月至2019年7月担任首席财务官。Murray先生自2014年10月起担任FLG Partners（一家金融咨询和顾问公司）的合伙人。在加入FLG Partners之前，Murray先生于2008年6月至2013年12月担任OptiMedica Corporation OptiMedica的首席财务官，该公司是一家眼科设备公司，于2013年被雅培实验室收购。在加入OptiMedica之前，Murray先生在Guidant Corporation工作了20多年，包括其前身Advanced Cardiovascular System及其继任者Abbott Labs。Murray先生在旧金山州立大学（San Francisco State University）获得工商管理（会计）学士学位。
Mark Murray has served as a member of our board of directors since October 2017 and previously served as our Chief Financial Officer from November 2017 until July 2019. Mr. Murray has served as a Partner at FLG Partners, a financial consulting and advisory company, since October 2014. Prior to FLG Partners, Mr. Murray served as Chief Financial Officer at OptiMedica Corporation OptiMedica, an ophthalmic device company which was acquired by Abbott Labs in 2013 from June 2008 to December 2013. Prior to OptiMedica, Mr. Murray spent over 20 years with Guidant Corporation, including its predecessor Advanced Cardiovascular System and its successor Abbott Labs. Mr. Murray received a B.S. in business administration (accounting) from San Francisco State University. - Mark Murray自2017年10月起担任董事会成员，此前曾于2017年11月至2019年7月担任首席财务官。Murray先生自2014年10月起担任FLG Partners（一家金融咨询和顾问公司）的合伙人。在加入FLG Partners之前，Murray先生于2008年6月至2013年12月担任OptiMedica Corporation OptiMedica的首席财务官，该公司是一家眼科设备公司，于2013年被雅培实验室收购。在加入OptiMedica之前，Murray先生在Guidant Corporation工作了20多年，包括其前身Advanced Cardiovascular System及其继任者Abbott Labs。Murray先生在旧金山州立大学（San Francisco State University）获得工商管理（会计）学士学位。
- Mark Murray has served as a member of our board of directors since October 2017 and previously served as our Chief Financial Officer from November 2017 until July 2019. Mr. Murray has served as a Partner at FLG Partners, a financial consulting and advisory company, since October 2014. Prior to FLG Partners, Mr. Murray served as Chief Financial Officer at OptiMedica Corporation OptiMedica, an ophthalmic device company which was acquired by Abbott Labs in 2013 from June 2008 to December 2013. Prior to OptiMedica, Mr. Murray spent over 20 years with Guidant Corporation, including its predecessor Advanced Cardiovascular System and its successor Abbott Labs. Mr. Murray received a B.S. in business administration (accounting) from San Francisco State University.
- Clare Ozawa
-
Clare Ozawa自2019年2月以来一直担任我们的董事会成员。Ozawa博士自2017年7月起担任Versant Venture Management LLC Versant（一家生命科学风险投资公司，投资于早期梦百合公司）的董事总经理，并于2008年至2011年担任Versant的投资专业人士。在重新加入Versant之前，小泽博士于2011年1月至2014年5月担任Inception Sciences（Inception）的首席商务官，并于2014年6月至2017年7月担任Inception’；的首席运营官。她也曾任职Novartis公司（从2006年到2008年）、McKinsey&Company（从2002年到2006年）的首席执行官办公室。Ozawa博士在斯坦福大学（Stanford University）获得生物科学学士学位和神经科学博士学位。
Clare Ozawa has served as a member of our board of directors since February 2019. Dr. Ozawa has served as a Managing Director at Versant Venture Management LLC Versant, a life science venture capital firm investing in early stage healthcare companies, since July 2017 and was an investment professional at Versant from 2008 to 2011. Prior to re-joining Versant, Dr. Ozawa was the Chief Business Officer of Inception Sciences (Inception) from January 2011 to May 2014 and served as Inception’s Chief Operating Officer from June 2014 to July 2017. She also worked in the Office of the Chief Executive Officer at Novartis from 2006 to 2008 and at McKinsey & Company from 2002 to 2006. Dr. Ozawa received a B.S. in biological sciences and a Ph.D. in neurosciences from Stanford University. - Clare Ozawa自2019年2月以来一直担任我们的董事会成员。Ozawa博士自2017年7月起担任Versant Venture Management LLC Versant（一家生命科学风险投资公司，投资于早期梦百合公司）的董事总经理，并于2008年至2011年担任Versant的投资专业人士。在重新加入Versant之前，小泽博士于2011年1月至2014年5月担任Inception Sciences（Inception）的首席商务官，并于2014年6月至2017年7月担任Inception’；的首席运营官。她也曾任职Novartis公司（从2006年到2008年）、McKinsey&Company（从2002年到2006年）的首席执行官办公室。Ozawa博士在斯坦福大学（Stanford University）获得生物科学学士学位和神经科学博士学位。
- Clare Ozawa has served as a member of our board of directors since February 2019. Dr. Ozawa has served as a Managing Director at Versant Venture Management LLC Versant, a life science venture capital firm investing in early stage healthcare companies, since July 2017 and was an investment professional at Versant from 2008 to 2011. Prior to re-joining Versant, Dr. Ozawa was the Chief Business Officer of Inception Sciences (Inception) from January 2011 to May 2014 and served as Inception’s Chief Operating Officer from June 2014 to July 2017. She also worked in the Office of the Chief Executive Officer at Novartis from 2006 to 2008 and at McKinsey & Company from 2002 to 2006. Dr. Ozawa received a B.S. in biological sciences and a Ph.D. in neurosciences from Stanford University.
- Benjamin Tsai
-
Benjamin Tsai自2019年2月以来一直担任我们的董事会成员。他于2008年加入Invus Opportunities公司，在那里他曾担任合伙人，专注于成长型股权投资。蔡先生曾担任十几家公司的董事或董事会观察员，主要是在医疗保健领域。此前，蔡先生是Monitor Group的管理顾问。蔡先生在南加州大学（University of Southern California）获得工商管理学士学位，在哈佛大学（Harvard University）获得工商管理硕士学位。
Benjamin Tsai has served as a member of our board of directors since February 2019. Mr. Tsai joined Invus Opportunities in 2008 where he is a partner focused on growth equity investments. Mr. Tsai has served as a director or board observer of more than a dozen companies, primarily in the health care sector. Previously, Mr. Tsai was a management consultant at the Monitor Group. Mr. Tsai received a B.S. degree in business administration from the University of Southern California and an M.B.A from Harvard University. - Benjamin Tsai自2019年2月以来一直担任我们的董事会成员。他于2008年加入Invus Opportunities公司，在那里他曾担任合伙人，专注于成长型股权投资。蔡先生曾担任十几家公司的董事或董事会观察员，主要是在医疗保健领域。此前，蔡先生是Monitor Group的管理顾问。蔡先生在南加州大学（University of Southern California）获得工商管理学士学位，在哈佛大学（Harvard University）获得工商管理硕士学位。
- Benjamin Tsai has served as a member of our board of directors since February 2019. Mr. Tsai joined Invus Opportunities in 2008 where he is a partner focused on growth equity investments. Mr. Tsai has served as a director or board observer of more than a dozen companies, primarily in the health care sector. Previously, Mr. Tsai was a management consultant at the Monitor Group. Mr. Tsai received a B.S. degree in business administration from the University of Southern California and an M.B.A from Harvard University.
- William J. Link
-
William J. Link，自2016年11月起担任董事会成员。Link博士于2017年成立了Flying L Management，LLC，是管理合伙人。自1999年以来，Link博士一直担任Versant Ventures Management LLC的董事总经理和联合创始人。2009年5月起担任爱德华兹生命科学 Corp.董事会成员，2015年7月起担任Oyster Point Pharma Pharma，Inc.董事会成员，2001年6月起担任Lensar，Inc.董事会成员，2017年11月起担任TERM3，Tarsus Pharmaceuticals，Inc.董事会成员。在1999年11月共同创立Versant Ventures之前，Link博士在1998年至2020年期间是Brentwood Venture Capital的普通合伙人。1986年3月至1997年12月，Link博士是Chiron Vision Corp.的创始人、董事长和首席执行官。他还创立并担任1978年至1985年被Allergan，Inc.收购的American Medical Optics，Inc.的总裁。Link博士于2002年9月至2009年2月担任Advanced Medical Optics，Inc.董事、于2003年7月至2014年2月担任Inogen公司董事、于2003年8月至2020年5月担任Second Sight医疗产品公司董事。Link博士还曾在1973年至1976年期间担任印第安纳大学医学院外科系的助理教授。Link博士获得普渡大学机械工程学学士、硕士和博士学位。
William J. Link has served as a member of board of directors since November 2016. Dr. Link formed Flying L Management, LLC in 2017 and is the Managing Partner. Dr. Link has served as a managing director and co-founder of Versant Ventures Management LLC, a venture capital firm investing in early stage healthcare companies, since 1999. He has served as a member of the board of directors of Edwards Lifesciences Corp. since May 2009 Oyster Point Pharma, Inc. since July 2015 Glaukos, Inc. since June 2001 Lensar, Inc. since November 2017 and Tarsus Pharmaceuticals, Inc. since January 2017. Prior to co-founding Versant Ventures in November 1999 Dr. Link was a general partner at Brentwood Venture Capital from 1998 to 2020. From March 1986 to December 1997 Dr. Link was founder, chairman, and chief executive officer of Chiron Vision Corp. He also founded and served as President of American Medical Optics, Inc. acquired by Allergan, Inc. from 1978 to 1985. Dr. Link served as a director of Advanced Medical Optics, Inc. from September 2002 to February 2009 a director of Inogen, Inc. from July 2003 to February 2014 and a director of Second Sight Medical Products, Inc. from August 2003 to May 2020. Dr. Link also served as an assistant professor in the Department of Surgery at the Indiana University School of Medicine from 1973 to 1976. Dr. Link received a B.S., M.S., and a Ph.D. in mechanical engineering from Purdue University. - William J. Link，自2016年11月起担任董事会成员。Link博士于2017年成立了Flying L Management，LLC，是管理合伙人。自1999年以来，Link博士一直担任Versant Ventures Management LLC的董事总经理和联合创始人。2009年5月起担任爱德华兹生命科学 Corp.董事会成员，2015年7月起担任Oyster Point Pharma Pharma，Inc.董事会成员，2001年6月起担任Lensar，Inc.董事会成员，2017年11月起担任TERM3，Tarsus Pharmaceuticals，Inc.董事会成员。在1999年11月共同创立Versant Ventures之前，Link博士在1998年至2020年期间是Brentwood Venture Capital的普通合伙人。1986年3月至1997年12月，Link博士是Chiron Vision Corp.的创始人、董事长和首席执行官。他还创立并担任1978年至1985年被Allergan，Inc.收购的American Medical Optics，Inc.的总裁。Link博士于2002年9月至2009年2月担任Advanced Medical Optics，Inc.董事、于2003年7月至2014年2月担任Inogen公司董事、于2003年8月至2020年5月担任Second Sight医疗产品公司董事。Link博士还曾在1973年至1976年期间担任印第安纳大学医学院外科系的助理教授。Link博士获得普渡大学机械工程学学士、硕士和博士学位。
- William J. Link has served as a member of board of directors since November 2016. Dr. Link formed Flying L Management, LLC in 2017 and is the Managing Partner. Dr. Link has served as a managing director and co-founder of Versant Ventures Management LLC, a venture capital firm investing in early stage healthcare companies, since 1999. He has served as a member of the board of directors of Edwards Lifesciences Corp. since May 2009 Oyster Point Pharma, Inc. since July 2015 Glaukos, Inc. since June 2001 Lensar, Inc. since November 2017 and Tarsus Pharmaceuticals, Inc. since January 2017. Prior to co-founding Versant Ventures in November 1999 Dr. Link was a general partner at Brentwood Venture Capital from 1998 to 2020. From March 1986 to December 1997 Dr. Link was founder, chairman, and chief executive officer of Chiron Vision Corp. He also founded and served as President of American Medical Optics, Inc. acquired by Allergan, Inc. from 1978 to 1985. Dr. Link served as a director of Advanced Medical Optics, Inc. from September 2002 to February 2009 a director of Inogen, Inc. from July 2003 to February 2014 and a director of Second Sight Medical Products, Inc. from August 2003 to May 2020. Dr. Link also served as an assistant professor in the Department of Surgery at the Indiana University School of Medicine from 1973 to 1976. Dr. Link received a B.S., M.S., and a Ph.D. in mechanical engineering from Purdue University.
高管简历
中英对照 | 中文 | 英文- Jeffrey Nau
Jeffrey Nau自2017年10月起担任我们的总裁兼首席执行官，并担任我们的董事会成员。从2017年3月至2017年10月，瑙博士作为顾问为我们提供服务。此前，Nau博士于2013年7月至2017年3月担任临床阶段生物制药公司Ophthotech Corporation Ophthotech临床和医疗事务Vice President。任职Ophthotech公司之前，他曾担任Genentech公司（生物技术公司）的医学科学董事（从2011年10月到2013年7月）。2006年9月至2011年10月，Nau博士担任Neovista的医疗和临床事务Vice President。Nau博士在石溪大学（Stony Brook University）获得生物学学士学位，在德雷克塞尔大学医学院（Drexel University College of Medicine）获得医学硕士学位，在沃尔登大学（Walden University）获得公共卫生与流行病学博士学位。
Jeffrey Nau has served as our President and Chief Executive Officer and as a member of our board of directors since October 2017. From March 2017 to October 2017 Dr. Nau provided services to us as a consultant. Previously, Dr. Nau was Vice President of Clinical and Medical Affairs at Ophthotech Corporation Ophthotech, a clinical-stage biopharmaceuticals company, from July 2013 to March 2017. Prior to Ophthotech, he was a Medical Science Director at Genentech, a biotechnology company, from October 2011 to July 2013. From September 2006 to October 2011 Dr. Nau was Vice President of Medical and Clinical Affairs at NeoVista. Dr. Nau received a B.S. in Biology from Stony Brook University, an M.S. in medical science from Drexel University College of Medicine, and a Ph.D. in public health and epidemiology from Walden University.- Jeffrey Nau自2017年10月起担任我们的总裁兼首席执行官，并担任我们的董事会成员。从2017年3月至2017年10月，瑙博士作为顾问为我们提供服务。此前，Nau博士于2013年7月至2017年3月担任临床阶段生物制药公司Ophthotech Corporation Ophthotech临床和医疗事务Vice President。任职Ophthotech公司之前，他曾担任Genentech公司（生物技术公司）的医学科学董事（从2011年10月到2013年7月）。2006年9月至2011年10月，Nau博士担任Neovista的医疗和临床事务Vice President。Nau博士在石溪大学（Stony Brook University）获得生物学学士学位，在德雷克塞尔大学医学院（Drexel University College of Medicine）获得医学硕士学位，在沃尔登大学（Walden University）获得公共卫生与流行病学博士学位。
- Jeffrey Nau has served as our President and Chief Executive Officer and as a member of our board of directors since October 2017. From March 2017 to October 2017 Dr. Nau provided services to us as a consultant. Previously, Dr. Nau was Vice President of Clinical and Medical Affairs at Ophthotech Corporation Ophthotech, a clinical-stage biopharmaceuticals company, from July 2013 to March 2017. Prior to Ophthotech, he was a Medical Science Director at Genentech, a biotechnology company, from October 2011 to July 2013. From September 2006 to October 2011 Dr. Nau was Vice President of Medical and Clinical Affairs at NeoVista. Dr. Nau received a B.S. in Biology from Stony Brook University, an M.S. in medical science from Drexel University College of Medicine, and a Ph.D. in public health and epidemiology from Walden University.
- Daniel Lochner
Daniel Lochner自2019年7月起担任我们的首席财务官。此前，Lochner先生是高盛（Goldman Sachs）投资管理部门的常务董事，他在该部门担任各种基金策略的首席股票投资组合经理和梦百合投资者。Lochner先生于2005年加入高盛（Goldman Sachs）的投资管理部门，担任股票投资者，他在该公司任职期间一直担任该职位。Lochner先生在里士满大学（University of Richmond）获得经济学学士学位，并在哥伦比亚大学（Columbia University）获得执行工商管理硕士学位。
Daniel Lochner has served as our Chief Financial Officer since July 2019. Previously, Mr. Lochner was a Managing Director within the Investment Management Division of Goldman Sachs where he served as a lead equity portfolio manager and healthcare investor for various fund strategies. Mr. Lochner joined the Investment Management Division of Goldman Sachs in 2005 as an equity investor, a position he maintained during his tenure at the firm. Mr. Lochner received a B.A. in Economics from the University of Richmond and an Executive M.B.A. from Columbia University.- Daniel Lochner自2019年7月起担任我们的首席财务官。此前，Lochner先生是高盛（Goldman Sachs）投资管理部门的常务董事，他在该部门担任各种基金策略的首席股票投资组合经理和梦百合投资者。Lochner先生于2005年加入高盛（Goldman Sachs）的投资管理部门，担任股票投资者，他在该公司任职期间一直担任该职位。Lochner先生在里士满大学（University of Richmond）获得经济学学士学位，并在哥伦比亚大学（Columbia University）获得执行工商管理硕士学位。
- Daniel Lochner has served as our Chief Financial Officer since July 2019. Previously, Mr. Lochner was a Managing Director within the Investment Management Division of Goldman Sachs where he served as a lead equity portfolio manager and healthcare investor for various fund strategies. Mr. Lochner joined the Investment Management Division of Goldman Sachs in 2005 as an equity investor, a position he maintained during his tenure at the firm. Mr. Lochner received a B.A. in Economics from the University of Richmond and an Executive M.B.A. from Columbia University.
- John Snisarenko
John Snisarenko自2019年9月起担任我们的首席商务官。Snisarenko先生最近于2017年6月至2019年9月担任Takeda Pharmaceuticals先前Shire眼科业务部的集团Vice President。在加入Shire之前，斯尼萨连科曾于2007年12月至2017年5月担任Genentech眼科业务部门的Vice President。2006年4月至2007年12月，Snisarenko先生是Novadaq Technologies眼科业务的Vice President，1996年6月至2006年4月，他是Novartis Pharmaceuticals Canada眼科业务的Vice President。Snisarenko先生自2019年7月起担任AlimeraSciences，Inc.（NASDAQ:ALIM）董事会成员。Snisarenko先生获得工商管理学士学位。McGill University生物化学硕士学位和工商管理硕士学位。
John Snisarenko,has been a member of the Board since July 2019. Mr. Snisarenko served as Chief Commercial Officer of Oyster Point Pharma, Inc. from September 2019 until his retirement in July 2022. He previously served as Group Vice President and Head of the Ophthalmics Franchise of Shire (now Takeda) from June 2017 until June 2019. Mr. Snisarenko led a large, multidisciplinary team in Shire's launch of Xiidra and also served as a member of Shire's Commercial Leadership Team. In 2019, Mr. Snisarenko was a key member in the divestiture of the Ophthalmology Franchise to Novartis Pharma. Prior to joining Shire, Mr. Snisarenko was the Franchise Head responsible for the commercial activities within Genentech's Ophthalmology (Lucentis) and Rheumatology (Rituxan, Actemra) franchises for 10 years. A 30 plus year veteran of the pharmaceutical/biotech industry, Mr. Snisarenko also held various positions of increasing responsibility at CIBA Vision / Novartis Pharma. In his last nine years, he served as Vice President and Business Unit Head for Novartis Ophthalmics, holding general management responsibilities for the Canadian business. Mr. Snisarenko has held numerous advisory board positions and was a board member for the Foundation Fighting Blindness in Canada. He holds a B.Sc. in Biochemistry and an MBA in Marketing and International Business from McGill University in Montreal, Canada.- John Snisarenko自2019年9月起担任我们的首席商务官。Snisarenko先生最近于2017年6月至2019年9月担任Takeda Pharmaceuticals先前Shire眼科业务部的集团Vice President。在加入Shire之前，斯尼萨连科曾于2007年12月至2017年5月担任Genentech眼科业务部门的Vice President。2006年4月至2007年12月，Snisarenko先生是Novadaq Technologies眼科业务的Vice President，1996年6月至2006年4月，他是Novartis Pharmaceuticals Canada眼科业务的Vice President。Snisarenko先生自2019年7月起担任AlimeraSciences，Inc.（NASDAQ:ALIM）董事会成员。Snisarenko先生获得工商管理学士学位。McGill University生物化学硕士学位和工商管理硕士学位。
- John Snisarenko,has been a member of the Board since July 2019. Mr. Snisarenko served as Chief Commercial Officer of Oyster Point Pharma, Inc. from September 2019 until his retirement in July 2022. He previously served as Group Vice President and Head of the Ophthalmics Franchise of Shire (now Takeda) from June 2017 until June 2019. Mr. Snisarenko led a large, multidisciplinary team in Shire's launch of Xiidra and also served as a member of Shire's Commercial Leadership Team. In 2019, Mr. Snisarenko was a key member in the divestiture of the Ophthalmology Franchise to Novartis Pharma. Prior to joining Shire, Mr. Snisarenko was the Franchise Head responsible for the commercial activities within Genentech's Ophthalmology (Lucentis) and Rheumatology (Rituxan, Actemra) franchises for 10 years. A 30 plus year veteran of the pharmaceutical/biotech industry, Mr. Snisarenko also held various positions of increasing responsibility at CIBA Vision / Novartis Pharma. In his last nine years, he served as Vice President and Business Unit Head for Novartis Ophthalmics, holding general management responsibilities for the Canadian business. Mr. Snisarenko has held numerous advisory board positions and was a board member for the Foundation Fighting Blindness in Canada. He holds a B.Sc. in Biochemistry and an MBA in Marketing and International Business from McGill University in Montreal, Canada.